The purpose of this study was to investigate the effects of creatine loading on rowing performance in well-trained male competitive rowers (age 19.4±0.2 yr, height 182.2 ± 1.2 cm, weight 76.6±1.1 kg, mean±SE) . Twenty subjects were randomly separated into creatine (n=10) or placebo group (n=10) . Subjects performed simulated 2000 m rowing race and 20 sec maximal rowing on a rowing ergometer, before and after 6 days of creatine (20g of creatine monohydrate plus 4g of lactose per day) or placebo (24g of lactose per day) ingestion, The creatine and placebo were administered in a double-blind research design. Performance time for 2000 m rowing was improved significantly from 407.9±5.3sec to 404.7±5.4sec (p<0.01) in the creatine group, but no significant changes were observed in the placebo group. No significant changes were observed in power output during 20 sec maximal rowing in either groups. These results suggest that creatine loading can enhance performance in simulated 2000 m rowing race in well-trained competitive male rowers but has no beneficial effect on 20 sec maximal rowing.

The purpose of this study was to determine the age and habitual physical activity on re-oxygenation time in working muscles following maximal cycling exercise (CycEXmax). Twelve sedentary middle-aged (50±6), 13 sedentary elderly (66±3), 13 active middle-aged (53±5), and 20 active elderly (67±5) were evaluated the half re-oxygenation time (T1/2 reoxy) as an index of oxygen delivery, using near-infrared spectroscopy at the vastus lateralis (VL) and lateral head of the gastrocnemius (LG) after CycEXmax. T1/2 reoxys at VL and LG were significantly greater in the elderly subjects than in the middle-aged subjects in both sedentary and active groups. T1/2 reoxys at VL and LG of the active group were smaller than those of the sedentary group, regardless of age. The results of this study suggest that habitual physical activity may attenuate age-related prolongation in T1/2 reoxy in working muscles although ageing delay T1/2 reoxy in working muscles.

Purpose: The objective of this study was to investigate whether body fat rate (BFR) and triceps skinfold thickness (TSF) are associated with estimated fentanyl absorption in patients treated with the fentanyl transdermal matrix patch for moderate to severe cancer pain, by measuring the residual content of fentanyl in used matrix patches. Methods: Adult Japanese inpatients experiencing chronic cancer-related pain and receiving treatment for the first time with a transdermal fentanyl matrix patch (Durotep®MT patch) were included in the present study. During the initial application period, BFR was measured using a body fat scale, and TSF was measured by an experienced nurse with an adipometer. One patch was collected from each patient. The residual fentanyl content in used matrix patch was determined by high-performance liquid chromatography. The transdermal fentanyl delivery efficiency was estimated based on the fentanyl content of the used matrix patches. Results: Fifteen adult patients (5 males and 10 females) were included in this study. Nine patches with a release rate of 12.5μg/h and 6 patches with a release rate of 25μg/h were collected. The application site was the chest or upper arm. BFR and TSF both showed a significant positive correlation with delivery efficiency. Conclusion: In malnourished or low-body fat patients receiving DMP, pain intensity should be more carefully monitored, and fentanyl dose adjustment may be required. Additional parameters, such as nutritional status including body fat change, the degree of dry skin, and plasma fentanyl concentration, also require detailed evaluation. Palliat Care Res 2010; 5(2): 206-212